Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News BMS announces Merck KGaA Erbitux study results

BMS announces Merck KGaA Erbitux study results

11th September 2008

Bristol-Myers Squibb (BMS) and ImClone Systems have announced the results of a new study showing the administration of Erbitux (cetuximab) plus platinum-based chemotherapy improved survival as a first-line treatment of recurrent or metastatic head and neck cancer.

Data from the phase III Extreme clinical study, conducted by Merck KGaA, was published in the New England Journal of Medicine.

The company said the treatment resulted in a significant improvements in the primary endpoint of the study – overall survival – as well as secondary endpoints of overall response rate and progression-free survival.

Patients receiving Erbitux with platinum-based chemotherapy showed an increase in median overall survival of 2.7 months when compared to those receiving chemotherapy alone.

Maurizio Voi, executive-director of oncology global medical affairs at BMS, said: “These results add to the growing body of Erbitux data for the treatment of head and neck cancer.”

He added that the company is continuing to explore and assess key questions regarding the potential of Erbitux to treat a range of cancers, with a focus on those with the highest unmet needs for therapy.

Last month, the Wall Street Journal said the success of plans by BMS to purchase ImClone Systems depends on the ownership of the rights to Erbitux.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.